A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Terbinafine (Primary)
- Indications Erythema
- Focus Adverse reactions; Therapeutic Use
- Sponsors Moberg Pharma
Most Recent Events
- 22 Apr 2024 New trial record